 | • レポートコード：MRC2203A010 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、世界の血液用ランセット市場規模が、年平均9％成長すると予測しています。本市場調査レポートでは、血液用ランセットの世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品種類別（安全ランセット、在宅医療用ランセット）分析、エンドユーザー別（病院、血液バンク、在宅医療、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の血液用ランセット市場規模：製品種類別（安全ランセット、在宅医療用ランセット） ・世界の血液用ランセット市場規模：エンドユーザー別（病院、血液バンク、在宅医療、その他） ・世界の血液用ランセット市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Becton, Dickinson and Company、F. Hoffmann-La Roche Ltd、B. Braun Melsungen AG、…） ・市場機会・将来傾向 |
The Blood Lancet Market is expected to register a CAGR of 9% during the forecast period. This is attributing to an increase in the incidence of chronic diseases, rising reimbursement policies, high prevalence of infectious diseases. Blood lancets are used to collect blood samples which is further used for monitoring purposes of several chronic diseases such as diabetes. In diabetes patients these blood lancets are widely used to check blood glucose levels. As per the Centers for Disease Control and Prevention, 6 in 10 adults in the United States are living with at least one type of chronic disease making chronic diseases a leading cause of death. Thus, the rising number of chronic diseases globally results in high adoption of blood lancet for diagnosing and monitoring purposes and drive the overall market. Furthermore, increasing inclination towards home healthcare devices with improving medical device regulation will also create a lucrative opportunity for the blood lancet market in the future.
Key Market Trends
Blood Lancet in Hospitals is Estimated to Witness a Healthy Growth in Future.
Blood Lancet in hospitals is estimated to witness a healthy growth in the future attributed to the growing number of chronic disease cases and infectious disease cases population. These targeted patient pools will require blood testing for diagnosing and treatment which is widely performed in hospitals thus results in promoting segment growth.
Homecare will also witness a significant growth in the coming years owing to a growing preference among the targeted population with benefits associated with blood lancets such as ease of use and simple design.
In Addition, as per International Diabetes Federation it is estimated that the number of diabetics population will be going to increase in the future which further fuels the blood lancet market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global Blood Lancet market due to the rising geriatric population, increasing targeted population, growing R&D expenses and growing awareness about diabetes treatment. As per Centers for Diseases Control and Prevention, in 2018 Around 34.2 million people in the United States had diabetes. Thus, with such a huge diabetic population will result in high demand for blood lancet for diagnosing and thus promotes the market in this region. Moreover, healthcare expenditure and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Competitive Landscape
The Blood Lancet Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, B. Braun Melsungen AG, Abbott, Terumo Corporation, ARKRAY, Owen Mumford Ltd, Intrinsyk, LLC., Sterimed, and Amkay Products Pvt. Ltd.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Incidence of Chronic Diseases
4.2.2 Rising Reimbursement Policies
4.2.3 High Prevalence of Infectious Diseases
4.3 Market Restraints
4.3.1 Reuse of Lancets
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Safety Lancet
5.1.2 Homecare Lancet
5.2 By End User
5.2.1 Hospitals
5.2.2 Blood Banks
5.2.3 Home Care
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 B. Braun Melsungen AG
6.1.4 Abbott
6.1.5 Terumo Corporation
6.1.6 ARKRAY
6.1.7 Owen Mumford Ltd
6.1.8 Intrinsyk, LLC.
6.1.9 Sterimed
6.1.10 Amkay Products Pvt. Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS